2026-06-14T03:54:58Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/179492024-09-27T12:12:05Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Rossello, Xavier
author
Rodriguez-Sinovas, Antonio
author
Vilahur, Gemma
author
Crisóstomo, Verónica
author
Jorge, Inmaculada
author
Zaragoza, Carlos
author
Zamorano, José L
author
Bermejo, Javier
author
Ordoñez, Antonio
author
Boscá, Lisardo
author
Vázquez, Jesús
author
Badimón, Lina
author
Sánchez-Margallo, Francisco M
author
Fernández-Avilés, Francisco
author
Garcia-Dorado, David
2024-02-10T20:02:48Z
2024-02-10T20:02:48Z
2019-12-30
10.1038/s41598-019-56613-6
2045-2322
Scientific reports
http://hdl.handle.net/10668/14905
31889088
http://hdl.handle.net/20.500.12105/17949
Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.
eng
CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions.
research article